Shares of Glenmark Pharmaceuticals rose 2.74 per cent on Thursday after the investment banking firm CLSA started covering the stock with 'buy' rating.
CLSA has set a target price of Rs 1,060 for the stock.
"The pharma major is at the cusp of a revival with pick-up in US approvals," says the investment firm.
Glenmark Pharmaceuticals has 24 "buys", six "holds" and one "sell" rating.
Shares of the company ended the day at Rs 914.10 on the Bombay Stock Exchange.
NYSE suspends trading of Infosys ADRs after 40% surge; Wipro ADRs soar
China eases rare earth export curbs for civilian use amid supply concerns. What it means for India 
Which companies will define the next decade of capital markets leadership? Here’s what BCG says
ED attaches assets of Yuvraj Singh, Sonu Sood, others in 1xBet money laundering case
Uday Kotak flags strategic question as Japan's MUFG makes ₹39,620-cr bet on Shriram Finance
Oneweb 2027 Plans: New Tech, New Features
Vinit Bolinjkar's 2026 Market Strategy: Be Selective And Valuation-Driven
Accenture Results Spark Fresh Buzz In IT, Early Turn Or Just A Bounce?
Hate Speech Bill Sparks Chaos In Karnataka Assembly, Opposition Cries Free Speech Attack
High-Profile Names Appear In New Epstein Photo Release Ahead Of Deadline
NYSE suspends trading of Infosys ADRs after 40% surge; Wipro ADRs soar
Lenskart Solutions shares rise 17% intra day as this brokerage turns bullish, more details 
Sensex jumps 447 pts, Nifty above 25,950; will rally continue next week?
Tagbin Services eyes IPO by 2027; raises $10 million from Ramesh Damani, Kurl-On & others
ICICI Prudential AMC shares slip below listing price; should you buy, sell or hold?